Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
Public ClinicalTrials.gov record NCT00285012. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With 40-Week Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate For Smoking Cessation In Patients With Mild-To-Moderate Chronic Obstructive Pulmonary Disease
Study identification
- NCT ID
- NCT00285012
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 504 participants
Conditions and interventions
Conditions
Interventions
- Varenicline Tartarate Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 35 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2006
- Primary completion
- Jun 30, 2008
- Completion
- Mar 31, 2009
- Last update posted
- Apr 19, 2010
2006 – 2009
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35249-2181 | — |
| Pfizer Investigational Site | Los Angeles | California | 90095-1690 | — |
| Pfizer Investigational Site | Los Angeles | California | 90095-6984 | — |
| Pfizer Investigational Site | Denver | Colorado | 80206 | — |
| Pfizer Investigational Site | Farmington | Connecticut | 06030-2810 | — |
| Pfizer Investigational Site | Farmington | Connecticut | 06030 | — |
| Pfizer Investigational Site | Miami | Florida | 33143 | — |
| Pfizer Investigational Site | Lexington | Kentucky | 40509 | — |
| Pfizer Investigational Site | Portland | Maine | 04102 | — |
| Pfizer Investigational Site | North Dartmouth | Massachusetts | 02747 | — |
| Pfizer Investigational Site | Rochester | Minnesota | 55905 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68198-5885 | — |
| Pfizer Investigational Site | Rochester | New York | 14609 | — |
| Pfizer Investigational Site | Chapel Hill | North Carolina | 27517 | — |
| Pfizer Investigational Site | Chapel Hill | North Carolina | 27599-7020 | — |
| Pfizer Investigational Site | Raleigh | North Carolina | 27607 | — |
| Pfizer Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| Pfizer Investigational Site | Winston-Salem | North Carolina | 27157 | — |
| Pfizer Investigational Site | Portland | Oregon | 97239-3098 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37203 | — |
| Pfizer Investigational Site | Houston | Texas | 77030-1608 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00285012, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2010 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00285012 live on ClinicalTrials.gov.